Diego Ferone Selected Research

Octreotide (Sandostatin)

4/2021	Octreotide and Pasireotide Combination Treatment in Somatotroph Tumor Cells: Predominant Role of SST2 in Mediating Ligand Effects.
12/2020	Use of octreotide long acting repeatable (LAR) as second-line therapy in advanced neuroendocrine tumors in different clinical settings: an Italian Delphi survey.
1/2020	Octreotide-Resistant Acromegaly: Challenges and Solutions.
2/2019	Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells.
1/2019	Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study.
6/2017	Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
1/2017	In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas.
10/2014	Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures.
12/2013	β-Arrestin 1 and 2 and G protein-coupled receptor kinase 2 expression in pituitary adenomas: role in the regulation of response to somatostatin analogue treatment in patients with acromegaly.
6/2012	Polycythemia as rare secondary direct manifestation of acromegaly: management and single-centre epidemiological data.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Diego Ferone Research Topics

Disease

37	Neoplasms (Cancer) 04/2021 - 02/2004
27	Acromegaly 04/2021 - 02/2004
20	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2021 - 07/2005
19	Pituitary Neoplasms (Pituitary Adenoma) 08/2019 - 06/2002
17	Adenoma (Adenomas) 02/2019 - 06/2002
7	Pituitary ACTH Hypersecretion 01/2020 - 05/2004
7	Cushing Syndrome 10/2019 - 06/2005
4	Growth Hormone-Secreting Pituitary Adenoma 02/2019 - 04/2008
3	Thyroid Neoplasms (Thyroid Cancer) 02/2022 - 05/2007
3	COVID-19 02/2021 - 08/2020
3	Carcinoma (Carcinomatosis) 01/2021 - 09/2004
3	ACTH-Secreting Pituitary Adenoma 01/2020 - 06/2014
3	Hyperthyroidism 06/2011 - 05/2007
2	Disease Progression 12/2020 - 01/2020
2	Chronic Disease (Chronic Diseases) 12/2020 - 09/2014
2	Melanoma (Melanoma, Malignant) 01/2018 - 12/2003
2	Fatigue 09/2017 - 04/2017
2	Primitive Neuroectodermal Tumors (PNET) 06/2017 - 10/2014
2	Carcinoid Tumor (Carcinoid) 04/2017 - 01/2007
2	Hypopituitarism (Sheehan's Syndrome) 03/2016 - 10/2015
2	Inflammation (Inflammations) 01/2014 - 10/2008
2	Carcinogenesis 01/2014 - 10/2013
2	Prolactinoma (Prolactinomas) 12/2013 - 04/2007
2	Hypothyroidism 08/2013 - 06/2009
2	Autoimmune Diseases (Autoimmune Disease) 01/2012 - 06/2006
2	Pheochromocytoma 06/2009 - 09/2004
2	Insulin Resistance 06/2009 - 09/2008
1	Vitamin D Deficiency 02/2021
1	medullary Thyroid cancer 01/2021
1	Pituitary Diseases (Disease, Anterior Pituitary) 12/2020
1	Type 2 Diabetes Mellitus (MODY) 03/2020
1	Gallstones (Gallstone) 01/2020
1	Pathologic Constriction (Stenosis) 01/2018
1	Cholelithiasis 09/2017
1	Atrophic Gastritis 06/2017
1	Metaplasia 06/2017
1	Headache (Headaches) 04/2017

Drug/Important Bio-Agent (IBA)

31	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/2021 - 02/2004
18	Somatostatin Receptors (Somatostatin Receptor)IBA 04/2021 - 07/2005
15	Octreotide (Sandostatin)FDA LinkGeneric 04/2021 - 07/2005
14	Growth Hormone (Somatotropin)IBA 04/2021 - 08/2008
11	Hormones (Hormone)IBA 01/2021 - 09/2004
10	Insulin-Like Growth Factor I (IGF-1)IBA 01/2021 - 02/2004
10	Dopamine Receptors (Dopamine Receptor)IBA 02/2014 - 05/2004
9	LigandsIBA 04/2021 - 07/2005
8	Adrenocorticotropic Hormone (ACTH)FDA Link 04/2017 - 05/2004
7	Dopamine (Intropin)FDA LinkGeneric 01/2021 - 12/2005
7	Dopamine Agonists (Dopamine Agonist)IBA 01/2020 - 05/2004
6	pasireotideIBA 04/2021 - 09/2014
6	Hydrocortisone (Cortisol)FDA LinkGeneric 01/2020 - 05/2004
5	Insulin (Novolin)FDA Link 01/2021 - 10/2007
5	Insulin-Like PeptidesIBA 12/2020 - 06/2009
5	Messenger RNA (mRNA)IBA 01/2020 - 08/2008
5	Biological ProductsIBA 08/2019 - 04/2007
5	Cabergoline FDA LinkGeneric 06/2011 - 05/2004
4	lanreotide (Somatuline)FDA Link 01/2021 - 06/2005
4	Peptide Receptors (Peptide Receptor)IBA 01/2021 - 01/2015
4	Thyrotropin (Thyroid-Stimulating Hormone)FDA Link 10/2015 - 09/2008
3	ArrestinIBA 01/2020 - 12/2013
3	ArrestinsIBA 01/2020 - 12/2013
3	Pharmaceutical PreparationsIBA 08/2017 - 01/2017
3	Proteins (Proteins, Gene)FDA Link 05/2016 - 10/2008
2	Vitamin D FDA LinkGeneric 02/2021 - 10/2013
2	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 08/2008
2	Everolimus FDA Link 12/2020 - 06/2017
2	Radioisotopes (Radionuclides)IBA 12/2020 - 08/2020
2	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2019 - 06/2006
2	TOR Serine-Threonine KinasesIBA 06/2017 - 02/2014
2	Chromogranin AIBA 06/2017 - 10/2014
2	ProlactinIBA 02/2015 - 04/2008
2	ChemokinesIBA 01/2014 - 08/2008
2	Glucose (Dextrose)FDA LinkGeneric 08/2013 - 06/2009
2	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 03/2013 - 01/2010
2	Dopamine D2 Receptors (Dopamine D2 Receptor)IBA 06/2011 - 12/2003
2	Thyroxine (Levothyroxine)FDA LinkGeneric 09/2008 - 05/2007
2	Dopamine Agents (Dopaminergic Agents)IBA 04/2007 - 04/2007
1	Phosphotransferases (Kinase)IBA 02/2022
1	Nucleocapsid ProteinsIBA 01/2021
1	Immune Checkpoint InhibitorsIBA 01/2021
1	Calcitonin (Calcitonin, Eel)FDA LinkGeneric 01/2021
1	Propidium (Propidium Iodide)IBA 01/2021
1	AntigensIBA 01/2021
1	thiazolyl blueIBA 01/2021
1	FITC-annexin A5IBA 01/2021
1	IncretinsIBA 03/2020
1	GlucocorticoidsIBA 01/2020
1	Nonsense Codon (Nonsense Mutation)IBA 10/2018
1	IpilimumabIBA 01/2018
1	enhanced green fluorescent proteinIBA 08/2017
1	3,3'- dioactadecyl- 5,5'- di(4- sulfophenyl)oxacarbocyanineIBA 08/2017
1	Pituitary HormonesIBA 01/2017
1	NestinIBA 01/2017
1	Insulin-Like Growth Factor II (Somatomedin A)IBA 08/2016

Therapy/Procedure

38	Therapeutics 04/2021 - 07/2005
7	Radiotherapy 01/2021 - 06/2002
4	Drug Therapy (Chemotherapy) 01/2021 - 02/2004
2	Biological Therapy 01/2015 - 01/2009
2	Aftercare (After-Treatment) 08/2009 - 02/2004
1	Combined Modality Therapy 01/2021
1	Immunotherapy 01/2021